Tumor and stromal chemoresistance

Alberto Villanueva Garatachea / David Garcia Mollevi

PRINCIPAL INVESTIGATORS
  • Maria Lourdes Farre Vallve
CLINICAL RESEARCHERS
  • Nuria Ruiz Roig
PREDOCTORAL RESEARCHERS
  • Natalia Molina Valdelvira
  • Daniel Alvarez Villanueva
SCIENTIFIC SUPPORT
  • Maria Bañuls Ferrando
  • Monica Calaf Sanjuanes
  • Maria Martinez Iniesta
Cancer
Oncobell

Scientific production

10

PAPERS

Average IF: 11,81

5

LED PAPERS

Average IF: 5,87

5 PUBLICATIONS IN FIRST DECILE

7 PUBLICATIONS IN FIRST QUARTILE

10 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Dias,MH;Friskes,A;Wang,SY;Neto,JMF;van Gemert,F;Mourragui,S;Papagianni,C et al, Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy, Cancer Discov., 2024;14(7):1276-1301, doi:10.1158/2159-8290.CD-23-0216
  • Nokin,MJ;Mira,A;Patrucco,E;Ricciuti,B;Cousin,S;Soubeyran,I;San José,S et al, RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade., Nat Commun, 2024;15(1):7554-7554, doi:10.1038/s41467-024-51828-2
  • Nokin,MJ;Mira,A;Patrucco,E;Ricciuti,B;Cousin,S;Soubeyran,I;San José,S et al, RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade., Nat Commun, 2024;15(1):7554-7554, doi:10.1038/s41467-024-51828-2
  • Nokin,MJ;Darbo,E;Richard,E;San José,S;de Hita,S;Prouzet Mauleon,V;Turcq,B et al, In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF V600E lung adenocarcinoma, Cell Rep Med, 2024;5(8):101663-101663, doi:10.1016/j.xcrm.2024.101663
  • Ortega Bertran,S;Fernández Rodríguez,J;Magallón Lorenz,M;Zhang,X;Creus Bachiller,E;Diazgranados,AP;Uriarte Arrazola,I et al, Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models., Clin Cancer Res, 2024;doi:10.1158/1078-0432.CCR-24-2807

Research highlights

PROJECTS

2 Granted competitive projects
6 Ongoing competitive projects

2 Ongoing clinical trials

INNOVATION

2 Licenses
1 Spin off

NETWORKS

LMRN

Selected projects

  • PI21/00270. Evaluación espacial del impacto del tratamiento neoadyuvante sobre el microambiente tumoral en las metástasis hepáticas de cáncer colorectal. Instituto de Salud Carlos III (ISCIII). Budget: 295.409,4€. 2022-2026. PI: GARCIA MOLLEVI, DAVID.
  • PI22/00548. Identificación de vulnerabilidades terapéuticas en cáncer de ovario y pulmón analizando las vías de reparación del ADN por Excisión de Nucleótidos (NER) y Recombinación Homóloga (HR). Instituto de Salud Carlos III (ISCIII). Budget: 214.170€. 2023-2025. PI: Villanueva Garatachea, Alberto.
  • EPPERMED2024-149. COLOSTEM-APPLY: Setting up and validating improved strategies for the identification and eradication of the poor prognosis fetal-type colorectal tumors. Generalitat de Catalunya. Budget: 199.989€. 2025-2027. PI: Villanueva Garatachea, Alberto.
  • FI20/00130. CONTRATOS PREDOCTORALES DE FORMACION EN INVESTIGACION EN SALUD (PFIS). Instituto de Salud Carlos III (ISCIII). Budget: 82400€. 2021-2025. PI: Villanueva Garatachea, Alberto.
  • 2022 FI_B 00309. FI (AGAUR) – 2022. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 67.425,11€. 2022-2025. PI: GARCIA MOLLEVI, DAVID.